TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: scar satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Platelet mitochondrial dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ATP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondrial membrane potential (Δ ψm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color alteration values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced expiratory volume (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum peak expiratory flow (PEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: psychomotor performance decline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in anxiety levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement at 60 minutes after injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival curves differences
Endpoint domain: Mortality/survival
Primary endpoint: Transient facial nerve weakness
Endpoint domain: Adverse events/effects
Primary endpoint: Parotid fistula formation
Endpoint domain: Adverse events/effects
Primary endpoint: Mean average time taken for surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mental Health Worries (MHW)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AST rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum suPAR concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: participants' balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response resolution rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h ambulatory measures of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resolution of DCS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colon cleansing effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality from lung cancer
Endpoint domain: Mortality/survival
Primary endpoint: nurses' quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Correct identification of treatment for gout
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual appeal of illustrated leaflets
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Understanding of the illness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rapid onset of unconsciousness
Endpoint domain: Adverse events/effects
Primary endpoint: Injection pain
Endpoint domain: Adverse events/effects
Primary endpoint: Transient tachycardia
Endpoint domain: Adverse events/effects
Primary endpoint: Composite end point of death, reinfarction, recurrent ischemia, new or worsening heart failure, or cardiogenic shock at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Access site bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Mild bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: total sputum eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: forced midexpiratory flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: self-efficacy related to physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: behavior related to healthy eating
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: quit rate for light-to-moderate smokers
Endpoint domain: Mortality/survival
Primary endpoint: Self-efficacy to refrain from smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confidence to quit smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: amygdala responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients meeting LDL-C goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain intensity after colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Traveling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Speed of diagnosis and treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoporosis screening rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Osteoporosis treatment rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CRP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VCAM-1 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Extubation failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moist desquamation
Endpoint domain: Adverse events/effects
Primary endpoint: naming performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: verbal communication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Best improvement in BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of central macular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of medical complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of severe nonfatal assault injury
Endpoint domain: Mortality/survival
Primary endpoint: Low TEG LY30
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in HAI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generalised anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incident CKD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean SEM latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip bone mineral density (BMD) loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Occurrence of stroke
Endpoint domain: Mortality/survival
Primary endpoint: Moderate or severe disability or death due to stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in MR imaging-related anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improved MR image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in ADSI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cesarean delivery rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean LTMH measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraobserver repeatability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of suture closure for sclerotomies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: measurement variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma free haemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: plasma haptoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increased number of concordant management plans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: General level of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Walking Impairment Questionnaire (WIQ) speed score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular Ejection Fraction (LV EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of akinetic segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regression of left ventricular hypertrophy (LVH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ETDRS visual acuity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Laparoscopic camera positioning stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase in CrossLaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Uterine microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Peak Expiratory Flow (PEF) growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1 growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in PVRi of greater than or equal to 20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal lip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lip force endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bet v 1-specific IgE and IgG(4) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mal d 1-specific T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nasal provocation scores to birch pollen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: IgG response to serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sexual function preservation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tl-201 washout rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Parental assessment scores for the child's perioperative experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean time to cessation of shivering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of shivering treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observer’s Assessment of Alertness/Sedation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for medication intake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 1-year relapse rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of hormone induced gynecomastia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of Raynaud's attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: LDL oxidation lag time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Weight gain rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale (VAS) at randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS decrease from randomization to the start of the PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heat pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Warfarin AUC((0-∞))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Warfarin C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: INR AUC((0-168 h))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fraction of recovered patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean values of IL‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recovery of neuromuscular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of persistent HPV-16 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of HPV-16-related cervical intraepithelial neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sperm function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: ROS levels decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: 12-month recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Inappropriate therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriate therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LOOH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy rates
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: failure to quit smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of microbiological failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rates of unsatisfactory clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child fruit and vegetable intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: children's mental development index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight-for-age Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in diffuse epigastric pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in epigastric distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of patients with excellent or good result at week 8
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction of pockets > 5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of seroprotected patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Responder rates (50% or greater reduction in seizure frequency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 6-month percent in-stent volume obstruction by IVUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early remission rates (HAMD < 8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of care options
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Desired role in self‐management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medical communication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of IANBs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of chest tube output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: UDI-6 scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clean intermittent catheterization rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: sTfR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DM incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alanine aminotransferase returned to normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: serum hepatitis C virus-RNA became negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: liver histology significantly improved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative for C trachomatis or C pneumoniae by PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sensitivity of SENS to detect progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of SENS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kappa coefficient (between-method agreement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of borderline intelligence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: greater disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: extrapyramidal side‐effects
Endpoint domain: Adverse events/effects
Primary endpoint: 3-day culture positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 7-day culture positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Shedding Index Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Knowledge scores of cardiopulmonary resuscitation options and terminology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gestational duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Antibiotic requirements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Symptomatic improvement speed
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: saggital diameter of the cervical spinal canal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of advanced neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: DAS (Disease Activity Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional independence at ICU discharge
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dose Limiting Toxicity (DLT) - grade 3 diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Partial responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stable disease for ≥ 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Smoking cessation rates at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: anginal class improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise duration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival free of adverse cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: Total exercise test duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGC-1α protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung elastance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lung collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean marginal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean PPD value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean BOP value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes